News
Novartis’ radioligand therapy granted US Breakthrough Therapy Designation
Swiss pharma company Novartis has scored a Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration for its investigational radioligand therapy Lu-PSMA-617.